Recurrence of central nervous system germinomas is rare; reports have been limited to within larger clinical trials and cohorts.
To our knowledge, there has not been a multi-institutional study that includes only patients with central nervous system germinomas.
Analysis of a retrospective cohort that includes patients from across multiple institutions and different treatment protocols may rpovide ingith into the treatment strategies and outcomes of this patient population, which will be valuable for understanding the management of this unique population.
